Open AccessInhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
Author(s) -
Xiaojun Ding,
Amanda C. Sharko,
Martina S.J. McDermott,
Gary P. Schools,
Alexander A. Chumanevich,
Hao Jiang,
Jing Li,
Li Zhang,
Zachary T. Mack,
Vitali Sikirzhytski,
Michael Shtutman,
Laura Ivers,
Norma O’Donovan,
John Crown,
Balázs Győrffy,
Mengqian Chen,
Igor B. Roninson,
Eugenia V. Broude
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2201073119
Subject(s) - lapatinib , cancer research , trastuzumab , pi3k/akt/mtor pathway , protein kinase b , reprogramming , tyrosine kinase , medicine , kinase , erbb , pharmacology , cancer , signal transduction , biology , breast cancer , cell , microbiology and biotechnology , biochemistry